Clinical trial
Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in…
NCT00069017 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00069017 |
|---|---|
| Title | Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate |
| Official title | A Phase II, Randomized, Double-Blind Study to Evaluate the Effects of MEDI-522, a Humanized MAb to Integrin Alpha V Beta 3, On Disease Activity and Progression of Joint Damage in Pts With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Biological, Other |
| Interventions | MEDI-522, Placebo |
| Enrollment | 300 |
| Start date | Sep 1, 2003 |
| Completion | Apr 1, 2006 |
| First posted | Sep 17, 2003 |
| Last update posted | Nov 27, 2007 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: